Skip to main content

Roche tests able to detect Omicron

| News

Roche tests able to detect Omicron


The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of the disease. These tests will serve research purposes. However, Roche diagnosis tests could also be used to detect Omicron infections in the future.

Roche logo on a building at the headquarters in Basel (img: Roche)

TIB Molbiol Syntheselabor GmbH, which was only taken over by Roche at the start of December, has developed a trio of new coronavirus tests, further details of which can be found in a press release issued by the Basel-based life sciences group. These tests are designed to uncover mutations seen in the new Omicron variant and are based on the quantitative polymerase chain reaction (PCR) method, which delivers the relevant results in real time. In presenting its new testing kits, Roche explains that they are among the first to specify the mutations of the recently discovered Omicron variant.

Employees at TIB Molbiol worked around the clock to develop the tests after the news broke regarding Omicron, explains Thomas Schinecker, CEO Roche Diagnostics. The tests could now help to improve understanding in connection with how Omicron spreads and behaves. This will benefit ongoing research and could accelerate the development of new treatments and vaccines.

While the new tests are to be exclusively used for research purposes, Roche also offers several coronavirus tests for diagnostic purposes. The SARS-CoV-2 Variant Set 1 test (RUO) is able to detect one of the mutations observed in the Omicron variants, meaning it can be used to diagnose Omicron cases, the press release explains.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.